inhibitors | Other agents | Disease | Dosage | Clinical trails | No Pts | Response | Reference |
---|
Tipifarnib | Bortezomib 1.0 mg/m2 | Elderly or relapsed AML | 300-600 mg bid, ×21d | Phase II | 80 | CR: 11% | [30] |
Tipifarnib | +/- etoposide | Elderly untreated AML | Â | Phase II | 107 | Safe | [31] |